



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/00, 39/35, 48/00, A61P 37/08	A2	(11) International Publication Number: WO 00/59538 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/US00/09461 (22) International Filing Date: 10 April 2000 (10.04.00) (30) Priority Data: 60/128,420 8 April 1999 (08.04.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/128,420 (CON) Filed on 8 April 1999 (08.04.99) (71) Applicant (for all designated States except US): THE JOHN HOPKINS UNIVERSITY [US/US]; Suite 906, 111 Market Place, Baltimore, MD 21201 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): AUGUST, J., Thomas [US/US]; 905 Poplar Hill Road, Baltimore, MD 21210 (US). LEONG, Kam, W. [US/US]; 10242 Breconshire Road, Ellicott City, MD 21042 (US). GEORGANTAS, Robert [US/US]; 16638 Arbor Terrace, Lockport, IL 60441 (US).		(74) Agents: KAGAN, Sarah et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ANTIGEN-SPECIFIC INDUCTION OF PERIPHERAL IMMUNE TOLERANCE (57) Abstract <p>Fas ligand (CD95L) induces apoptosis in activated T cells through the process of Activation Induced Cell Death (AICD). Gelatin nanoparticles are virus sized gelatin-protein-DNA complexes which can encapsulate multiple DNA vectors and proteins, and which are thought to act by increasing in vivo transfection of antigen presenting cells. By injecting mice with gelatin nanoparticles containing a murine Fas ligand (CD95L) DNA vector and a β-galactosidase (LacZ) model antigen vector, the T cell response specific for β-gal was ablated without effecting the response to a secondary antigen. In effect, this "tolerization" injection induces antigen specific peripheral tolerance in study mice, and is applicable to the treatment of autoimmune diseases when self-antigens such as Myelin Basic Protein are co-delivered with the Fas ligand.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTIGEN-SPECIFIC INDUCTION OF PERIPHERAL IMMUNE TOLERANCE

TECHNICAL FIELD OF THE INVENTION

5 This invention is related to the area of immune diseases. More particularly it relates to autoimmune diseases, allergic diseases, and transplantation rejection.

BACKGROUND OF THE INVENTION

10 Immunologic tolerance to self antigens is a necessary mechanism for protecting an organism from destruction by its own immune system. When this mechanism malfunctions, allowing self-reactive immune cells to proliferate, an autoimmune disease develops within the host. A number of diseases such as Multiple Sclerosis, Lupis, Myathenia Gravis, and Rheumatoid Arthritis have been shown to result from loss of self-tolerance in T and B lymphocytes.

15 Fas ligand (CD95L) plays a substantial role in both the regulation [1] [2] and effector function [3] of the immune system, as well as in the maintenance of immunologic privilege [4] [5] [6-8]. T lymphocytes utilize CD95L to induce apoptosis in target cells, and also become susceptible to CD95L after antigen stimulation through the processes of Activation Induced
20 Cell Death (AICD). [9] [10] T lymphocytes reactive with self-proteins play a substantial role in autoimmune pathology [11]. For example, Myelin reactive T cells have been demonstrated in patients with Multiple Sclerosis

[12] [13] [14] and in the experimental autoimmune encephelomyelitis mouse and rat models have been shown to be both pathogenic and able to transfer disease between syngeneic animals. [15-18]

5 There is a continuing need in the art for additional methods and tools for treating autoimmune diseases, as well as allergic diseases and transplantation rejection.

SUMMARY OF THE INVENTION

10 It is an object of the present invention to provide a method of ablating or reducing a pathological immune response, such as an autoimmune response, an allergic response, or transplantation rejection.

It is another object of the present invention to provide compositions of nanospheres, antigen presenting cells, nucleic acid expression vectors, or liposomes useful for ablating or reducing an immune response.

15 These and other objects of the invention are achieved by providing a method in which nucleic acids are administered to a mammal. The nucleic acids encode a first and a second protein which are a molecule which induces apoptosis or inactivation of T cells and a pathogenic antigen, respectively. Antigen presenting cells express both the first protein and the second protein. Antigen-specific T cells are activated by the antigen presenting cells which
20 express the pathogenic antigen. Activated antigen-specific T cells are killed or inactivated by the first protein expressed by the antigen presenting cells. Thus an immune response to the antigen can be ablated.

25 Also provided are nanospheres which comprise at least one nucleic acid molecule encoding a first and a second protein. The first protein induces apoptosis or inactivation of T cells, and the second protein comprises a pathogenic antigen. The pathogenic antigen is capable of activating antigen-specific T cells. The first protein is capable of killing or inactivating activated antigen-specific T cells.

30 Also provided by the present invention is a composition comprising a liposome which comprises at least one nucleic acid molecule encoding a first and a second protein. The first protein induces apoptosis or inactivation

of T cells, and the second protein comprises a pathogenic antigen. The pathogenic antigen is capable of activating antigen-specific T cells and the first protein is capable of killing or inactivating activated antigen-specific T cells.

5 According to another embodiment of the invention a composition is provided which comprises a nucleic acid vector encoding a first and a second protein. The first protein induces apoptosis or inactivation of T cells, and the second protein comprises a pathogenic antigen. The pathogenic antigen is capable of activating antigen-specific T cells and the first protein is capable
10 of killing or inactivating activated antigen-specific T cells.

In yet another embodiment of the invention a composition comprising a genetically engineered cell is provided. The cell comprises at least one nucleic acid molecule encoding a first and a second protein. The first protein induces apoptosis or inactivation of T cells, and the second protein comprises
15 a pathogenic antigen. The pathogenic antigen is capable of activating antigen-specific T cells and the first protein is capable of killing or inactivating activated antigen-specific T cells.

The present invention thus provides the art with methods and compositions useful for treating autoimmune diseases, transplantation rejection, and allergic diseases.
20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. *Fas ligand/Lac Z co-delivery abrogates the CTL immune response to β -gal.* Mice were injected and re-injected at 2 weeks with saline alone (●), 1 μ g of p43-FasL DNA in nanoparticles (■), 1 μ g of p43-cLacZ in nanoparticles (◆), 1 μ g of LacZ/FasL in nanoparticles (▲), or 1 μ g of
25 p43-cLacZ in nanoparticles in one leg and 1 μ g of p43-FasL in nanoparticles in the opposite leg (▼). T cells were isolated from the spleen and lymph nodes of the mice and assayed for β -gal specific cytotoxicity.

Figure 2. *Systemic abrogation of the β -gal CTL immune response by Fas ligand/LacZ co-delivery.* Mice were three times at two week intervals with
30 saline alone (●), 50 μ g of p43-FasL naked DNA in the left leg (■), 50 μ g of

p43-FasL naked DNA in the left leg and LacZ/FasL DNA nanoparticles (2 μ g of DNA total) in the right leg (\blacklozenge), 100 μ g of p43-FasL naked DNA in the left leg (\blacktriangle), or 100 μ g of p43-FasL naked DNA in the left leg and LacZ/FasL DNA nanoparticles (2 μ g of DNA total) in the right leg (\blacktriangledown). T cells were isolated from the spleen and lymph nodes of the mice and assayed for β -gal specific cytotoxicity.

Figure 3. *Antigen specific induction of tolerance by LacZ/FasL nanoparticles.* Mice were injected at 0, 2, and 4 weeks with saline (\bullet), p43-cLacZ nanoparticles (1 μ g) (\blacksquare), LacZ/FasL nanoparticles (2 μ g) (\blacklozenge), p43-cLacZ nanoparticles (1 μ g) in the left leg (\blacktriangle), or p43-cLacZ nanoparticles (1 μ g) in the right leg and pcHA vector (50 μ g) in the left leg (\blacktriangledown). T cells harvested from the spleen and lymph nodes of and were assayed for CTL response against β -gal (**Figure 3A**) or to HA (**Figure 3B**).

Figure 4. *Requirement for co-delivery of Fas ligand and LacZ vectors.* Mice were injected at 0, 2, and 4 weeks with saline (\blacktriangledown), 50 μ g of naked p43-LacZ (\bullet), 50 μ g of naked p43-LacZ in the left leg and LacZ/FasL DNA nanoparticles (2 μ g of DNA total) in the right leg (\blacksquare), 50 μ g of naked p43-cLacZ (\blacklozenge), a mixture of 50 μ g of p43-cLacZ and 50 μ g of p43-FasL (\blacktriangle). Two weeks after the final injections, T cells were harvested from the spleen and lymph nodes and were assayed for CTL response against β -gal.

Figure 5. *The effects of LacZ/FasL nanoparticle injection on β -Gal immunity of pre- and post-immunized mice.* Mice were injected with saline (\bullet), three times with 1 μ g of p43-LacZ nanoparticles (\blacksquare), three times with 50 μ g of naked p43-LacZ (\blacklozenge), twice with 2 μ g of LacZ/FasL nanoparticles followed by three times with 1 μ g of p43-LacZ in nanoparticles (\blacktriangle), or three times with 1 μ g of p43-LacZ nanoparticles followed by twice with 2 μ g of LacZ/fasL nanoparticles (\blacktriangledown). AL1 immunization injections were given at 2-week intervals and tolerizing injections were given at 1-week intervals. Three weeks after the final injection, T cells were isolated from the spleen and lymph nodes and were assayed for β -Gal-specific cytotoxicity.

DETAILED DESCRIPTION

It is a discovery of the present inventors that co-expression within individual cells of a pathogenic antigen and a cell protein which kills or inactivates activated T cells leads to activation and antigen-induced cell death (AICD) in reactive T cells. It is believed that interaction of T cells with protein epitopes bound in the MHC class I and II molecules of antigen presenting cells (APCs) leads to antigen-specific activation of T cells. These activated T cells then interact with a cell protein which inactivates or kills activated T cells, inducing these T cells to undergo apoptosis. It is a further finding of the inventors that nanospheres formed by coacervation of more than one coding sequence are efficient means of achieving co-transfection, without requiring special digenic constructs.

Pathogenic antigens according to the present invention are those against which a pathological immune reaction is directed. Thus the antigen can be, for example, an allergen, an autoantigen, or a transplantation antigen.

Autoimmune antigens are relevant to several diseases, including Multiple Sclerosis, Rheumatoid Arthritis, Myasthenia gravis, and Lupus Erythematosus. Other diseases in which an autoimmune component has been implicated are Insulin Dependent Diabetes Mellitus, and Crohn's disease.

Nucleic acids encoding the pathogenic antigen of choice may include a targeting signal directing the protein to the MHC class II antigen presentation system. One particularly preferred targeting system is the LAMP-1 targeting system. See U.S. Pat. No. 5633234, which is expressly incorporated herein. The LAMP targeting system guides proteins to the endosomal/lysosomal system for processing and presentation. LAMP-mediated lysosomal targeting of antigens has been shown to increase the immune reaction to the antigen through a mechanism of increased antigen presentation to CD4+ T helper cells. In contrast, no particular targeting system is required to achieve antigen presentation in the MHC class I system. Presentation via the MHC class I system activates CD8+ cytotoxic T cells. Activation and subsequent deletion of the CD4+ and CD8+ populations abrogates both antibody and cellular immune responses.

Nucleic acids can be used which encode any cellular protein which induces apoptosis or inactivation of T cells. The cellular protein can be a surface protein or a secreted protein for which the activated T cells express a receptor. Preferably expression of the receptor is up-regulated upon activation of the T cells. Suitable cellular proteins include, without limitation, Fas ligand and TNF α . Secreted proteins such as cytokines and chemokines can be used as well.

Ablation of an immune response includes reduction, alleviation, amelioration and total elimination. The immune response can be evaluated by measuring any relevant biological component of the immune system or by evaluating symptoms of a patient or mammal being treated. See, Chapter 2, "The Induction, Measurement, and Manipulation of the Immune response," in *Immunobiology, the immune system in health and disease*, Janeway, Travers, Hunt, and Walport, Current Biology Limited, NY, 1997. Preferably a reduction of at least 25% is achieved. More preferably a reduction of at least 50%, 75%, 80%, 85%, 90%, or 95% is achieved.

Administration of nucleic acids according to the invention can be according to any procedure known in the art. While delivery of nanospheres which coacervate both coding sequences is desired, other delivery systems as are known in the art can be used, including but not limited to liposomes, viral particles, naked DNA, gene guns, and the like. Cells which have been transfected *ex vivo* can also be used for delivery of the nucleic acids to a mammal. Cells can be antigen presenting cells or muscle cells. Preferably they are autologous. Although applicants do not wish to be bound by any particular theory or mechanism of operation, it appears that co-transfection of cells with both components, the coding sequence for the pathogenic antigen and the coding sequence for the cellular protein which induces apoptosis or inactivation, is required. Thus methods which maximize the probability of cotransfection are preferred. The two coding sequences can be on a single molecule of nucleic acid or they can be physically associated in a complex, for example. Those of skill in the art will be able to choose the precise configuration which is most convenient for the particular application at hand.

Uptake of the nucleic acids by antigen presenting cells can be accomplished as is known in the art. See Akbari et al., *J. Exp. Med.* 189:169-177; Casares et al, *J. Exp. Med.* 186:1481-1486; Condon et al, *Nature Medicine* 2:1122-1128; and Porgador et al, *J. Exp. Med.* 188:1075-1082. If
5 a targeting moiety is desired to increase the number of antigen presenting cells which take up the DNA, one can target N418, CD83, MHC class II, CD80 and CD86 (B7.1 and B7.2) and CD40. For example, antibodies or antibody portions which are specific for these cell makers can be attached to the nanospheres.

10 Expression vectors which are useful according to the present invention are molecules which will ensure transcription and translation of the encoded proteins. Appropriate expression vectors are known in the art for mammalian cells and in particular for human cells. The promoters used may be constitutive or regulated. The expression units for the apoptosis-inducing
15 protein and the pathogenic antigen may be on one or two distinct molecules.

Liposomes are well known in the art. Any technique may be used for making the liposomes at the choice of the skilled artisan. The liposomes can co-encapsulate two distinct expression vectors or one vector which encodes both the pathogenic antigen and the apoptosis-inducing protein.

20 Modes of administration to the mammal or patient can be by any conventional route. These include, but are not limited to subcutaneous, intramuscular, intravenous, intraperitoneal, oral, intranasal, intrabronchial, and scarification. While it is believed that the present method works by *in vivo* uptake of the DNA directly by antigen presenting cells, it is possible that other
25 cells such as muscle cells take up the DNA as well.

Nanospheres typically are coacervates of a positively charged and a negatively charged polymer. Nanospheres which employ nucleic acids as the negatively charged polymer can employ, for example, gelatin, chitosan, or derivatives thereof as the positively charged polymer. The nanospheres
30 preferably are less than 5 μm and more preferably less than 3 μm . A population of nanospheres can be sized. Whereas there may be some

variability in the size of the population the size of at least 50%, 75%, 85%, or 90% of the population can be applied as characterizing the population.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Injection of Mice with LacZ/FasL nanoparticles

Immunization of mice with gelatin nanoparticles containing a β -gal encoding p43-cLacZ vector had been previously shown to produce a large antigen specific immune reaction in mice. Also, protein molecules such as cytokines, which effect the immune system, could be encapsulated and co-delivered with the DNA vector nanoparticles resulting in a shift in the immune response toward a Th1 or Th2 bias. [25]

Since our theoretical model for antigen specific deletion of T cells required that individual cells be co-transfected with both antigen-encoding and fas ligand-encoding vectors, we tested the effect on the immune system of injecting mice with LacZ/FasL nanoparticles as compared to LacZ only nanoparticles.

We found that a normal immune response to the β -gal protein is generated when mice are immunized with LacZ vector alone or with LacZ in one leg and Fas ligand in the opposite leg (Figure 1). When co-encapsulated LacZ and Fas ligand are injected, the immune reaction against β -gal is reduced to background reactivity, similar to the group injected with saline alone. Injection of Fas ligand nanoparticles alone had no effect on the immune response. Thus, the co-delivery of a Fas ligand expression vector and an antigen-encoding vector leads to abrogation of the CTL response to the antigen.

Methods: DNA Vectors

The p43-cLacZ vector encoding the E. coli β -galactosidase gene has been previously described [26]. The Fas ligand mRNA sequence was

obtained by PCR of the gene from the pCI-FasL vector, which was the generous gift of Dr. Berry Burns. Primers for PCR of the gene sequence, sense 5'--3' and antisense 5'--3', contained EcoR I linkers. The p43-FasL vector encoding the C57B/6 mouse mRNA sequence was constructed by ligation of the DNA fragment into the EcoR I restriction site of the p43 DNA vector, and the resulting construct was sequenced by the Biochemistry Core facility to assure sequence integrity. Both vectors were propagated in DH5 cells, and were purified using the Qiagen EndoFree Plasmid Kits. Purified plasmid DNA was assayed for bacterial LPS contamination.

Materials: Mice

6-8 week old BALB/c mice were purchased from the Charles Rivers Laboratories. All protocols for animal use were approved.

Methods: Immunization of animals

Gelatin nanoparticles were prepared as described [24, 25] and DNA loading level was quantitated by Fluorimetry after digestion with 2.5% trypsin to release the DNA from the gelatin. Mice were immunized by intramuscular injection in tibialis anterior muscle of the rear legs with naked DNA or gelatin nanoparticles suspended in sterile saline solution.

Methods: Cytotoxic T cell Assay

Lymph nodes and spleens were harvested from mice and T cells isolated by non-adherence to nylon wool as previously described and were assayed for antigen specific cytotoxicity by chromium release assay as previously described [27] [25]. Chromium release was quantitated on a Packard TopCount NXT, and results expressed as Counts \times min⁻¹ (CPM)

EXAMPLE 2

Systemic Abrogation of T cell Activity

Although activated APCs become refractory to apoptosis and specifically to Fas ligand mediated apoptosis by down-regulation the Fas receptor, the possibility was raised that the expression of the Fas ligand on the surface of transfected APC's was inducing auto-apoptosis of the APC, thereby killing or inactivating the APC before it was able to interact with T cells,

thereby preventing it from ever inducing an immune reaction to the antigen. To rule out this possibility, mice were immunized in one leg with a high dose of naked p43-cLacZ and in the opposite leg with LacZ/FasL nanoparticles (Figure 2). Our reasoning being that if Fas ligand expression was simply causing auto-apoptosis of transfected cells, the immune response generated in the opposite leg injected with naked p43c-cLacZ would not effected. On the other hand, expression of antigen and the Fas ligand by individual APCs and muscle cells, which would display both activating antigen and AICD-inducing fas ligand to T cells, should lead to systemic deletion of β -gal reactive T cells.

Mice injected with naked p43-cLacZ alone developed strong CTL responses to β -gal, whereas those injected with naked p43-cLacZ in one leg and LacZ/FasL nanoparticles in the opposite leg developed responses only slightly higher than that of the group injected with saline alone. Thus, the co-delivery of fas ligand- and LacZ-encoding vectors leads to systemic abrogation of the immune response by a mechanism other than inducing apoptosis in the transfected APCs.

EXAMPLE 3

Abrogation of T cell Activity in Mice Immunized with Antigen Before or After Tolerization.

LacZ/FasL nanoparticles systemically abrogate the β -gal specific immuneresponse when injected at the same time as an immunization, clearly effecting the development of an immune response. However, the effectiveness against pre-existing T cells or against antigen-specific precursor T cells was not known. To answer these questions, mice were immunized three times with p43-cLacZ nanoparticles before or after injection of LacZ/FasL nanoparticles.

EXAMPLE 4

Antigen Specific Induction of T cell Tolerance

Having demonstrated that LacZ/FasL tolerization nanoparticles ("Tol nanospheres") abrogate both the local and systemic immune reaction to β -gal, we next asked if the tolerization injection would affect the immune response

to a second antigen injected at a separate site. Mice were injected in one leg with the pCHA vector and in the opposite leg with LacZ/FasL nanoparticles. While co-delivery of LacZ and Fas ligand resulted in abrogation of the β -gal specific response (Figure 3A), the immune response to influenza hemmagglutinin (HA) was not affected (Figure 3B). These data demonstrate that the deletion of T cells induced by the LacZ/FasL nanoparticles is antigen-specific, and that the phenomenon does not affect secondary antigens that are not co-expressed with the fas ligand.

EXAMPLE 5

Requirement of Vector Co-Delivery

Our model of the tolerization system assumed that a co-delivery system is necessary to ensure co-expression of antigen and Fas ligand within individual cells. To test if co-delivery was in fact required (Figure 4), mice were injected with naked p43-cLacZ (50 μ g), naked p43-cLacZ (50 μ g) and LacZ/FasL nanoparticles (2 μ g), naked p43-FasL (50 μ g), or a mixture of naked p43-cLacZ (50 μ g) and p43-FasL (50 μ g). Harvested T cells were assayed for CTL activity against β -gal. The saline and p43-FasL immunization groups did not show β -gal-specific lysis activity. The p43-cLacZ group developed a strong response to β -gal. The LacZ/FasL (Tol nanospheres) with p43-cLacZ nanoparticles resulted in the abrogation of the response. The group injected with naked LacZ and FasL vectors showed only a small decrease in the immune response compared to the decrease observed in the nanoparticle group. Therefore, although a small decrease in the immune response was observed after injection of the naked vectors, co-delivery is a requirement for the abrogation of the immune response to an antigen.

In this study we have attempted to induce peripheral tolerance of T lymphocytes by taking advantage of the phenomena of Activation Induced Cell Death, in which activated T cells become susceptible to induction of apoptosis by the fas ligand. An immune response to an antigen is initiated when an APC expressing antigen in surface bound MHC class molecules

interacts with a CD4+ T helper lymphocytes. The CD4+ cell becomes activated and at the same time displays the CD40 ligand (CD154), which fully activates the APC. The APC is then able to activate CD8+ T cytotoxic lymphocytes through display of antigen on surface-bound MHC class I molecules. We speculated that co-expressing antigen and fas ligand on individual cells might cause antigen-specific activation of T cells and induction of AICD through interaction with CD95L.

We co-encapsulated two separate DNA vectors, one encoding the CD95L and one the β -galactosidase model antigen, within gelatin nanoparticles. Gelatin nanoparticles are a coacervate of DNA and gelatin that have previously been demonstrated to have utility in vaccine delivery and in gene therapy applications. See U.S. Serial Nos. 08/657,913, filed June 7, 1996, 60/071,679, filed January 16, 1998; and 60/071,746, filed January 16, 1998, which are expressly incorporated herein. Our theory of CD95L induced tolerance required that both the antigen and CD95L genes be co-expressed in individual cells. We tested nanoparticles for the ability to deliver two distinct nucleic acid constructs to the same cell without the need of building elaborate digeneic DNA constructs.

We have shown that T cells reactive to a specific antigen are deleted in mice injected with nanoparticles encoding both the specific antigen and a surface molecule which induces apoptosis.

EXAMPLE 6

Multiple Sclerosis Antigens: Myelin Basic Protein

An excellent MS model exists in the SJL/J strain of mice which mirrors the human disease in both its pathology and immunological characteristics. This disease model, called experimental allergic encephalomyelitis (EAE), is used to characterize the tolerization technique for prevention and treatment of multiple sclerosis.

The myelin basic protein mRNA sequence from the SJL/J mouse was cloned by RT-PCR into a mammalian expression vector. It was subsequently subcloned into a tPA-TmC chimera mammalian expression vector.

Expression of myelin basic protein with the fas ligand is used to delete mouse T cells reactive with myelin basic protein, as described above for β -galactosidase.

EXAMPLE 7

5 **Inhibition of CTL activity of pre- or postimmunized mice**

10 LacZ/FasL DNA nanoparticles systemically inhibited the β -Gal-specific CTL response when injected into mice at the same time as administration of the immunizing DNA. We have also tested the effectiveness of the tolerization method in mice with T cells already present from a previous antigen challenge or against rechallenge with antigen after the tolerization injection (Fig. 5). Mice were injected twice with LacZ/FasL DNA nanoparticles (2 μ g of DNA) either 2 weeks before or 2 weeks after they were immunized three times with 1 μ g of p43-cLacZ nanoparticles. There was no significant CTL response in mice injected twice with LacZ/FasL nanoparticles before immunization with nanoparticles containing p43-cLacZ DNA alone, yielding T cell reactivity similar to that of mice injected with saline alone. Mice immunized three times with p43-cLacZ nanoparticles and then injected with LacZ/FasL nanoparticles 7 and 14 days after the last immunization showed a great decrease in, but not complete abrogation of, T cell reactivity compared with mice injected with 1 μ g of p43-cLacZ nanoparticles or with 50 μ g of naked p43-cLacZ. Within the time frame of this experiment, injection of the LacZ/FasL nanoparticles prevented the development of a β -Gal-specific T cell response to antigen challenge after the mice had been tolerized. Also, LacZ/fasL nanoparticles were able to markedly reduce, but not completely abrogate, the T cell reactivity to antigen generated by immunization before tolerization injections were administered.

References

1. Van Parijs, L.A., A.K., Homeostasis and self-tolerance in the immune system: turning lymphocytes off. *Science*, 1998. 280(5361): p. 243-248.
2. Wang, J.L., M. J., Molecules involved in cell death and peripheral tolerance. *Current Opinion in Immunology*, 1997. 9(6): p. 818-825.
3. Podack, E.R., Functional significance of two cytotoxic pathways of cytotoxic T lymphocytes. *Journal of Leukocyte Biology*, 1995. 57: p. 548-552.
4. Greil, R.E., A. Villunger, A., On The Role And Significance Of Fas (Apo-1/CD95) Ligand (FasL) Expression In Immune Privileged Tissues And Cancer Cells Using Multiple Myeloma As A Model. *Leukemia & Lymphoma*, 1998. 31(5-6): p. 477.
5. Green, D.R.W., Carl F., Fas-ligand: Privilege and peril. *Proceedings of the National Academy of Sciences*, 1997. 94: p. 5989-5990.
6. Griffith, T.S.B., T. Fletcher, S.M. Green, D.R. Ferguson, T.A., Fas ligand-induced apoptosis as a mechanism of immune privilege. *Science*, 1995. 270(5239): p. 1189-1192.
7. Griffith, T.S.F., Thomas A., The role of FasL-induced apoptosis in immune privilege. *Immunology Today*, 1997. 18(5): p. 240-244.
8. Griffith, T.S.Y., X. Herndon, J.M. Green, D.R. Ferguson, T.A., CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. *Immunity*, 1996. 5(1): p. 7-16.
9. Green, D.R.S., David W., Activation-induced apoptosis in lymphocytes. *Current opinion in Immunology*, 1994. 6: p. 476-487.
10. Wong, B.A., Joseph Choi, Yongwon, T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. *Journal of experimental medicine*, 1997. 186(11): p. 1939.
11. Bach, J.F.K., S. Vanendert, P.M., Are there unique autoantigens triggering autoimmune diseases. *Immunological Reviews*, 1998. 164: p. 139-155.
12. Vrethem, M.D., C. Ekerfelt, C. Forsberg, P. Danielsson, O. Ernerudh, J., CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood

from patients with multiple sclerosis, meningitis and normal controls. *Acta Neurologica Scandinavica*, 1998. 97(4): p. 215-220.

13. de Rosbo, N.K.H., Michael Ben-Nun, Avraham, Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple

sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. *European journal of immunology*, 1997. 27(11): p. 3059.

14. Boiko, A.N.F., O.O., Multiple sclerosis - molecular and cell mechanisms. *Molecular Biology*, 1995. 29(4): p. 413-426.

15. Patterson, P.Y., Transfer of allergic encephalitis in rats by means of lymph node cells. *Journal of experimental medicine*, 1960. 111: p. 119-133.

16. Trotter, J., et al., Characterization of T cell lines and clones from SJL/J and (BALB/cxSJL/J)F1 mice specific for myelin basic protein. *Journal of Immunology*, 1985. 134: p. 2322-2327.

17. Ben-Nun, A., H. Wererle, and I.R. Cohen, The rapid isolation of clonable antigen-specific lymphocyte lines capable of mediating autoimmune encephalomyelitis. *European Journal of Immunology*, 1981. 11: p. 195-199.

18. Lyons, J.-A., M.-L. Zhao, and R.B. Fritz, Pathogenesis of acute passive murine encephalomyelitis I. Importance of host-derived cells as determined by kinetic analysis. *Journal of neuroimmunology*, 1998. 86: p. 92-103.

19. Maecker, H.U., D.T. DeKruyff, R.H. Levy, S., Cytotoxic T cell responses to

DNA vaccination: Dependence on antigen presentation via class II MHC. *Journal of Immunology*, 1998. 161(12): p. 6532-6536.

20. Akbari, O.P., N. Garcia, S. Tascon, R. Lowrie, D. Stockinger, B., DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. *Journal of Experimental Medicine*, 1999. 189(1): p. 169-177.

21. Chattergoon, M.A.R., Tara M. Weiner, David B., Specific Immune Induction

Following DNA-Based Immunization Through In Vivo Transfection and Activation

of Macrophages/Antigen-Presenting Cells. *Journal of immunology*, 1998.

160(12): p. 5707.

22. Porgador, A.I., KR Iwasaki, A Barber, BH Restifo, NP Germain, RN.,
Predominant Role For Directly Transfected Dendritic Cells In Antigen
Presentation To CD8(+)T Cells After Gene Gun Immunization. Journal of
Experimental Medicine, 1998. 188(6): p. 1075-1082.

23. Donnelly, J.J., et al., DNA vaccines. Annual Review of Immunology,
1997.

15: p. 617-48.

24. Truong-Le, V.L.W., Scott M. Schweibert, Erik Mao, Hai-Quan Guggino,
William B. August, J. Thomas Leong, Kam W., Gene transfer by DNA-gelatin
nanospheres. Archives of Biochemistry and Biophysics, 1999. 361(1): p.
47-56.

25. Truong-Le, V.L., et al., DNA-Gelatin nanoarticles as vaccines:
immunologic effects of co-delivered cytokine proteins and protection against
ebola virus. in preperation, .

26. Troung, V.L., in Pharmacology and Molecular Science. 1998, Maryland:
Baltimore.

27. Coligan, J.E., in Current Protocols in Immunology. 1994.

All articles, texts, and patents cited in this application are expressly
incorporated herein by reference.

CLAIMS

1. A method of reducing an antigen-specific immune response, comprising:

administering nucleic acids to a mammal, wherein the nucleic acids encode a first and a second protein, wherein the first protein induces apoptosis or inactivation of T cells, and the second protein is a pathogenic antigen, whereby an immune response to the antigen in the mammal is reduced.

2. The method of claim 1 wherein antigen presenting cells in the mammal take up the nucleic acids, whereby the antigen presenting cells express the first protein and the second protein, whereby antigen-specific T cells are activated and killed.

3. The method of claim 1 wherein the nucleic acids are administered to the mammal by delivery of antigen presenting cells which comprise the nucleic acids.

4. The method of claim 1 wherein the nucleic acids are administered to the mammal by delivery of muscle cells which comprise the nucleic acids.

5. The method of claim 1 wherein the first and the second proteins are encoded by separate nucleic acid molecules.

6. The method of claim 1 wherein the pathogenic antigen is an allergen.

7. The method of claim 1 wherein the pathogenic antigen is an autoimmune antigen.

8. The method of claim 7 wherein the autoimmune antigen is one to which the mammal mounts an immune response.

9. The method of claim 1 wherein the pathogenic antigen is a transplantation antigen.

10. The method of claim 2 wherein the first protein is expressed on the surface of the antigen presenting cells.

11. The method of claim 2 wherein the first protein is secreted by the antigen presenting cells.

12. The method of claim 1 wherein the first protein is Fas ligand.

13. The method of claim 1 wherein the first protein is Tnf- α .

5 14. The method of claim 1 wherein the second protein is lysosomally targeted.

15. The method of claim 1 wherein the second protein is not lysosomally targeted.

10 16. The method of claim 2 wherein receptors for the first protein on T cells are up-regulated upon activation of the T cells.

17. The method of claim 1 wherein the nucleic acid molecules are coacervated in nanospheres.

18. The method of claim 5 wherein the nucleic acid molecules are coacervated in nanospheres.

15 19. The method of claim 14 wherein a CD4+ T helper cell population is killed.

20. The method of claim 15 wherein a CD8+ cytolytic T cell population is killed.

20 21. The method of claim 1 wherein the antigen is myelin basic protein.

22. A composition comprising a nanosphere which comprises at least one nucleic acid molecule encoding a first and a second protein, wherein the first protein induces apoptosis or inactivation of activated T cells, and the second protein comprises a pathogenic antigen, wherein the pathogenic antigen is capable of activating antigen-specific T cells.

25 23. A composition comprising a liposome which comprises at least one nucleic acid molecule encoding a first and a second protein, wherein the first protein induces apoptosis or inactivation of activated T cells, and the second protein comprises a pathogenic antigen, wherein the pathogenic antigen is capable of activating antigen-specific T cells.

30 24. A composition comprising a nucleic acid expression vector encoding a first and a second protein, wherein the first protein induces

apoptosis or inactivation of activated T cells, and the second protein comprises a pathogenic antigen, wherein the pathogenic antigen is capable of activating antigen-specific T cells.

5 25. A composition comprising an antigen presenting cell which comprises at least one nucleic acid molecule encoding a first and a second protein, wherein the first protein induces apoptosis or inactivation of activated T cells, and the second protein comprises a pathogenic antigen, wherein the pathogenic antigen is capable of activating antigen-specific T cells, wherein the antigen presenting cell expresses both the first and the second proteins.

10 26. The composition of claim 22, 23, or 25 wherein the first and the second proteins are encoded by separate nucleic acid molecules.

 27. The composition of claim 22, 23, 24, or 25 wherein the pathogenic antigen is an allergen.

15 28. The composition of claim 22, 23, 24, or 25 wherein the pathogenic antigen is an autoimmune antigen.

 29. The composition of claim 22, 23, 24, or 25 wherein the pathogenic antigen is a transplantation antigen.

 30. The composition of claim 22, 23, 24, or 25 wherein the first protein is a cell surface protein.

20 31. The composition of claim 22, 23, 24, or 25 wherein the first protein is Fas ligand.

 32. The composition of claim 22, 23, 24, or 25 wherein the first protein is TNF- α .

25 33. The composition of claim 22, 23, 24, or 25 wherein the second protein is lysosomally targeted.

 34. The composition of claim 22, 23, 24, or 25 wherein the second protein is not lysosomally targeted.

 35. The composition of claim 22, 23, 24, or 25 wherein receptors for the first protein on T cells are up-regulated upon activation of the T cells.

30 36. The composition of claim 33 wherein a CD4⁺ T helper cell population is targeted.

37. The composition of claim 34 wherein a CD8+ cytolytic T cell population is targeted.

38. The composition of claim 22, 23, 24, or 25 wherein the antigen is myelin basic protein.

5

FIG. 1




FIG. 2




FIG. 3




Fig 3B

Fig 3A

FIG. 4





Fig 5



THIS PAGE BLANK (USPIO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 October 2000 (12.10.2000)

PCT

(10) International Publication Number
WO 00/59538 A3

- (51) International Patent Classification⁷: A61K 39/00, 39/35, 48/00, A61P 37/08
- (21) International Application Number: PCT/US00/09461
- (22) International Filing Date: 10 April 2000 (10.04.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/128,420 8 April 1999 (08.04.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/128,420 (CON)
Filed on 8 April 1999 (08.04.1999)
- (71) Applicant (for all designated States except US): THE JOHN HOPKINS UNIVERSITY [US/US]; Suite 906, 111 Market Place, Baltimore, MD 21201 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AUGUST, J., Thomas [US/US]; 905 Poplar Hill Road, Baltimore, MD 21210 (US). LEONG, Kam, W. [US/US]; 10242 Breconshire Road, Ellicott City, MD 21042 (US). GEORGANTAS, Robert [US/US]; 16638 Arbor Terrace, Lockport, IL 60441 (US).
- (74) Agents: KAGAN, Sarah et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- (88) Date of publication of the international search report:
22 March 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIGEN-SPECIFIC INDUCTION OF PERIPHERAL IMMUNE TOLERANCE

(57) Abstract: Fas ligand (CD95L) induces apoptosis in activated T cells through the process of Activation Induced Cell Death (AICD). Gelatin nanoparticles are virus sized gelatin-protein-DNA complexes which can encapsulate multiple DNA vectors and proteins, and which are thought to act by increasing in vivo transfection of antigen presenting cells. By injecting mice with gelatin nanoparticles containing a murine Fas ligand (CD95L) DNA vector and a β -galactosidase (LacZ) model antigen vector, the T cell response specific for β -gal was ablated without effecting the response to a secondary antigen. In effect, this "tolerization" injection induces antigen specific peripheral tolerance in study mice, and is applicable to the treatment of autoimmune diseases when self-antigens such as Myelin Basic Protein are co-delivered with the Fas ligand.

WO 00/59538 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/09461

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/00 A61K39/35 A61K48/00 A61P37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	------------------------------------------------------------------------------------	-----------------------

Y	<p>WO 98 21951 A (HAAS SUSAN ;MILSTEIN SAM J (US); EMISPHERE TECH INC (US)) 28 May 1998 (1998-05-28) page 2, line 21 -page 4, line 15 page 6, line 4 -page 8, line 6 ---</p>	1-38
---	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 October 2000

Date of mailing of the international search report

09/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/09461

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ZHANG ET AL: "INDUCTION OF SPECIFIC T CELL TOLERANCE BY FAS LIGAND-EXPRESSING ANTIGEN-PRESENTING CELLS"</p> <p>JOURNAL OF IMMUNOLOGY, vol. 162, 1 February 1999 (1999-02-01), pages 1423-1430, XP002151202 page 1424, paragraph 2 page 1425, paragraph 1 - paragraph 3 page 1425, paragraph 4 -page 1426, paragraph 2 page 1426, paragraph 3 -page 1428, paragraph 1 page 1429, paragraph 5</p>	1-38
A	<p>SATA M ET AL: "Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, no. 3, 3 February 1998 (1998-02-03), pages 1213-1217, XP002147595 ISSN: 0027-8424 page 1216, paragraph 2 - paragraph 3; figures 4,5</p>	1-38
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1997 (1997-11) DAY CHARLES S ET AL: "Myoblast-mediated gene transfer to the joint." Database accession no. PREV199800175990 XP002151203 abstract & JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 15, no. 6, November 1997 (1997-11), pages 894-903, ISSN: 0736-0266</p>	4

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/09461

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 15 October 1998 (1998-10-15) JOSIEN REGIS ET AL: "Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance." Database accession no. PREV199800511546 XP002151204 abstract & TRANSPLANTATION (BALTIMORE), vol. 66, no. 7, 15 October 1998 (1998-10-15), pages 887-893, ISSN: 0041-1337</p>	13,32
A	<p>US 5 633 234 A (AUGUST J THOMAS ET AL) 27 May 1997 (1997-05-27) cited in the application column 8, line 2 -column 9, line 34</p>	14,19
A	<p>LEONG K W ET AL: "DNA-polycation nanospheres as non-viral gene delivery vehicles" JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 53, no. 1-3, 30 April 1998 (1998-04-30), pages 183-193, XP004121269 ISSN: 0168-3659 page 183 abstract</p>	17,18,22
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995 GAO X ET AL: "Cationic liposome-mediated gene transfer." Database accession no. PREV199698648544 XP002151205 abstract & GENE THERAPY, vol. 2, no. 10, 1995, pages 710-722, ISSN: 0969-7128</p>	23
A	<p>ARAI H ET AL: "INHIBITION OF THE ALLOANTIBODY RESPONSE BY CD95 LIGAND" NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 3, no. 8, August 1997 (1997-08), pages 843-848, XP002910396 ISSN: 1078-8956 page 843 abstract</p>	19,20, 36,37

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/09461

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9821951 A	28-05-1998	CA 2243643 A EP 0886471 A	28-05-1998 30-12-1998
US 5633234 A	27-05-1997	AT 180835 T CA 2154445 A DE 69418856 D DE 69418856 T DK 680513 T EP 0680513 A ES 2132395 T GR 3031026 T JP 8505878 T WO 9417192 A	15-06-1999 04-08-1994 08-07-1999 20-01-2000 27-12-1999 08-11-1995 16-08-1999 31-12-1999 25-06-1996 04-08-1994

THIS PAGE BLANK (USPTO)